Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2019-2025

Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
In 2018, the global Gene Modifying Immunotherapy for Blood Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio

Market segment by Type, the product can be split into

CAR T-cell Therapy
TCR T-cell Therapy

Market segment by Application, split into

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players.
To present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Gene Modifying Immunotherapy for Blood Cancer are as follows:
History Year: 2014-2018

Base Year:

2018

Estimated Year:

2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.